NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the...

NeoStem, Inc. Appoints Financial Expert with Broad International Experience to
the Board of Directors and to Serve as Chairman of the Company's Audit
Committee

NEW YORK, June 10 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), which is
pioneering the pre-disease collection, processing and long-term storage of
adult stem cells for future medical need, announced today it has appointed to
its Board of Directors Drew Bernstein, CPA and Managing Partner of Bernstein &
Pinchuk LLP, to serve as the Chairman of the Company's Audit Committee.

Mr. Bernstein co-founded Bernstein & Pinchuk LLP (B&P) in 1983, a fast growing
accounting firm headquartered in New York, which is an independent member of
the BDO Seidman Alliance. His early recognition of the global marketplace and
his extensive travel in the People's Republic of China ("PRC") resulted in the
aggressive expansion of the firm's services to the PRC where he has
established associate offices to better serve expanding client needs. In
addition, his diverse experience in retail, manufacturing, hospitality,
professional practices and real estate contributed to the expansion of the
firm's client base abroad. Fluent in the French language, Mr. Bernstein serves
as an accountant and business advisor worldwide, providing specialized
auditing and accounting services to public and non-public companies throughout
the United States of America, China, Europe and Africa.

Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are very
pleased to welcome Mr. Bernstein to the Board of NeoStem and as chair of our
Audit Committee. His broad international business experience will provide the
insight and expertise we need as we grow our nationwide network of stem cell
collection centers, expand our business operations into China, develop our
VSEL (very small embryonic-like stem cells) technology with the University of
Louisville, and strengthen our focus on international medical tourism to serve
people seeking medical treatments not yet available in their own nations. Mr.
Bernstein's diverse knowledge and abilities will support our successful growth
in these complex arenas."

Mr. Bernstein stated, "I'm delighted to join the Board of NeoStem Inc. I look
forward to working with the highly intelligent, creative people that Dr. Smith
has assembled and to helping this extraordinary Company advance its innovative
potential."

About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are
focused on enabling people to donate and store their own (autologous) stem
cells when they are young and healthy for their personal use in times of
future medical need. The Company has also entered into research and
development through the acquisition of a worldwide exclusive license to
technology to identify and isolate VSELs (very small embryonic-like stem
cells), which have been shown to have several physical characteristics that
are generally found in embryonic stem cells and is pursuing other technologies
to advance its position in the field of stem cell tissue regeneration.

For more information, please visit: www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could
cause future results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors" described
in the Company's Annual Report on Form 10-K for the fiscal year ended December
31, 2008 and the Company's other periodic filings with the Securities and
Exchange Commission. The Company's further development is highly dependent on
future medical and research developments and market acceptance, which is
outside its control.

CONTACT:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com

SOURCE NeoStem, Inc.

Robin Smith, Chief Executive Officer of NeoStem, Inc., +1-212-584-4180,
rsmith@neostem.com